Drug profile · INN
frovatriptan succinate
FROVATRIPTAN SUCCINATE
frovatriptan succinate (FROVATRIPTAN SUCCINATE) is a serotonin 1b (5-ht1b) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — frovatriptan succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
frovatriptan succinate (FROVATRIPTAN SUCCINATE) is a serotonin 1b (5-ht1b) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 1b (5-HT1b) receptor agonist
Primary target: 5-hydroxytryptamine receptor 1B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is frovatriptan succinate?
frovatriptan succinate (FROVATRIPTAN SUCCINATE) is a serotonin 1b (5-ht1b) receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for frovatriptan succinate?
FROVATRIPTAN SUCCINATE is a marketed brand name for frovatriptan succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of frovatriptan succinate?
frovatriptan succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.